Loading stock data…
Cogent Biosciences (COGT)
$35.28+0.52 (+1.50%)
Market ClosedLast close Sep 8
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cogent Biosciences, Inc. in the Healthcare sector is trading at $35.28 with a market capitalization of $5.6B. Wall Street consensus targets $55.82 (11 analysts), implying a +58.2% move over the next 12 months. The stock is currently 19% below its 52-week high of $43.73, remaining 4.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +58.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$103.61M↓ | -$99.49M↓ | -$83.36M↓ | -$75.58M↓ | -$74.93M |
| Net Income | -$97.35M↑ | -$102.49M↓ | -$80.93M↓ | -$73.53M↓ | -$71.99M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.57B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-58.30%
Volume
Today's trading volume
2.24M
Recent News
Biotech ETF (CANC) Hits New 52-Week High
CANC hits a 52-week high as strong oncology developments and positive momentum fuel the biotech ETF's rally.
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Cogent Biosciences (COGT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Cogent Bioscience (COGT) Files New Drug Application For Bezuclastinib
Cogent Biosciences Inc. (NASDAQ:COGT) is one of the 10 affordable biotech stocks to buy right now. On June 30, Cogent Bioscience Inc. (NASDAQ:COGT) disclosed that it filed a New Drug Application for bezuclastinib, a drug for the treatment of Advanced Systemic Mastocytosis. The application to the U.S. FDA is backed by encouraging clinical results from […]
Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market?
Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the most promising healthcare stocks according to Wall Street analysts. On June 12, Cogent Biosciences, Inc. (NASDAQ:COGT) presented early-stage preclinical data for its experimental drug CGT1145 at the European Hematology Association Congress in Stockholm, Sweden. The company presented the drug candidate as a potentially more precise and better-tolerated […]
Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial
Cogent Biosciences (COGT) Bezuclastinib showed "rapid and deep" clinical benefit and met primary and